OneDigital Investment Advisors LLC Invests $288,000 in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

OneDigital Investment Advisors LLC acquired a new stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 3,164 shares of the company's stock, valued at approximately $288,000.

A number of other hedge funds also recently made changes to their positions in the stock. Daiwa Securities Group Inc. grew its stake in shares of BioNTech by 7.1% during the 4th quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock valued at $221,000 after acquiring an additional 128 shares during the period. Bank of New York Mellon Corp boosted its stake in BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after purchasing an additional 150 shares during the period. Probity Advisors Inc. boosted its stake in BioNTech by 8.5% in the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock worth $224,000 after purchasing an additional 154 shares during the period. Midwest Professional Planners LTD. boosted its stake in BioNTech by 5.8% in the 4th quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock worth $462,000 after purchasing an additional 222 shares during the period. Finally, Jones Financial Companies Lllp boosted its stake in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after purchasing an additional 246 shares during the period. 15.52% of the stock is currently owned by institutional investors.

BioNTech Trading Down 0.9%

BNTX stock traded down $1.03 during midday trading on Friday, reaching $112.89. The company's stock had a trading volume of 521,908 shares, compared to its average volume of 943,543. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. The stock has a fifty day simple moving average of $103.56 and a two-hundred day simple moving average of $106.81. BioNTech SE Sponsored ADR has a 1 year low of $76.53 and a 1 year high of $131.49. The firm has a market capitalization of $27.14 billion, a price-to-earnings ratio of -33.20 and a beta of 1.29.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on BNTX shares. Citigroup restated a "buy" rating and issued a $140.00 price target (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. The Goldman Sachs Group started coverage on BioNTech in a research note on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price target for the company. Morgan Stanley set a $133.00 price objective on BioNTech and gave the stock an "overweight" rating in a report on Thursday. Leerink Partners set a $112.00 price objective on BioNTech in a report on Monday, June 2nd. Finally, Truist Financial reaffirmed a "buy" rating and set a $155.00 price objective (up from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, BioNTech has a consensus rating of "Moderate Buy" and an average target price of $137.91.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.